- The Richest Members of the US Congress
- New Consensus Sees Stimulus Package as Worthy Step
- Wall Street Jobs Slow to Return Despite Record Profits
- Thanksgiving Week Stuffed With Economic News
- Black Friday Deals May Not Signal Retail Comeback
- Investors to Goldman: Be Less Greedy
- UPS Sets New Rates For 2010
- Victoria's Secret Hopes to Rekindle Desire for Lingerie
- 'New Moon' Takes Record $72.7M Box Office Bite
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
- Holiday Tipping: Who And How Much
- Deep Discounts Should Make It a Very Tech-y Holiday
Text Size 
An analyst sounded a warning note on shares of biotechnology company Dendreon on Monday, which have more than tripled in value since March 30, but the stock continued to rise.
A Food and Drug Administration panel endorsed Provenge, a prostate cancer vaccine, on March 30, saying there was evidence the drug could be an effective cancer fighter. The agency usually follows panel recommendations in evaluating new drug applications.
Brean Murray Carret & Co. analyst Jonathan Aschoff said the FDA would set a "dangerous double standard" by approving Provenge, which did not meet its primary goal in two phase III trials. He said the FDA rejected Pharmacyclics' new drug application for Xcytrin for not reaching its goals, but agreed to review the Provenge application.
Aschoff has "Sell" rating and a price target of $1.50 for shares of Seattle-based Dendreon, implying the stock will lose 91.7 percent of its value in the next year.
Five of the nine analysts reporting to Thomson Financial rate Dendreon stock at "Buy" or the equivalent. Two analysts rate it at "Neutral"-equivalent and two at "Sell"-equivalent.
Dendreon were up [DNDN
Loading...
()
] on the Nasdaq Stock Market. The stock hit a new all-time high of $21 shortly after the open Monday.
Print
Email
- Technology can make or break a fortune in the world of alternative energy.
- Many people are facing the holidays with substantially smaller incomes. Here’s how some are adapting.
- Jim Cramer is a proponent of stocks that pay healthy dividends, and here are his top five dividend plays.
- From salt, to lip balm to envelopes, it turns out that bacon flavoring can sell almost anything.
- The homebuyer's tax credit jacked sales for a while, but 2010 is looking weak. Now what?
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes